The U.S. District Court for the Northern District of Texas on December 14, 2018, issued a decision striking down the Patient Protection and Affordable Care Act (ACA).
The case is: Texas v. United States, 4:18-cv-00167-O (N.D. Tex. December 14, 2018). Read the district court’s decision
The court held that, following passage of the U.S. tax law referred to as the “Tax Cuts and Jobs Act of 2017” (TCJA), the “individual mandate provision” in the ACA is unconstitutional and the remaining provisions of the ACA are inseverable and are, therefore, invalid.
At the same time, the court refused a request for an injunction by the plaintiffs, so the ACA will continue in full force and effect until after an appeal is decided. The Department of Health and Human Services has indicated in a press release that it will continue to enforce the ACA. Attorneys General from several states and industry group leaders confirmed that an appeal would be filed with the U.S. Court of Appeals for the Fifth Circuit.
Importantly, it is not expected that the case will be resolved in the coming months; indeed, it could take years.
As noted above, the nature of the decision leaves the ACA in force for now. As a result, all current taxes enacted as part of the ACA likewise remain in effect, pending appeal of the case.
Depending upon the outcome of that appeal, the case could eventually end up before the U.S. Supreme Court. Ultimately, a number of different outcomes are possible. The decision could be upheld in full, reversed in part (i.e., an appellate court could decide that the individual mandate is unconstitutional but is severable from all or part of the law and the rest of the law stands), or reversed in full.
If the decision ultimately were to be upheld in full (i.e., without modification), it would have far-reaching implications, resulting in a rollback of all provisions of the ACA—including all of the taxes and fees contained in the ACA. These include, for example, the additional “HI” tax on high-income individuals as well as a variety of healthcare industry taxes and fees.
It is not clear, however, what the potential impact of the case ultimately being upheld might be on tax provisions contained in a separate bill that was enacted in conjunction with the ACA—the “Health Care and Education Reconciliation Act of 2010,” Pub. L. No. 111-152. Tax provisions included in this separate bill include: the medical device excise tax (Code section 4191), the 3.8% tax on net investment income (section 1411), and the codification of the economic substance doctrine (section 7701(o)).
For more information, contact a tax professional in KPMG's Washington National Tax practice:
Lori Robbins | +1 (202) 533-3491 | firstname.lastname@example.org
Monica Coakley | +1 (615) 248-5639 | email@example.com
The KPMG logo and name are trademarks of KPMG International. KPMG International is a Swiss cooperative that serves as a coordinating entity for a network of independent member firms. KPMG International provides no audit or other client services. Such services are provided solely by member firms in their respective geographic areas. KPMG International and its member firms are legally distinct and separate entities. They are not and nothing contained herein shall be construed to place these entities in the relationship of parents, subsidiaries, agents, partners, or joint venturers. No member firm has any authority (actual, apparent, implied or otherwise) to obligate or bind KPMG International or any member firm in any manner whatsoever. The information contained in herein is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavor to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act on such information without appropriate professional advice after a thorough examination of the particular situation. For more information, contact KPMG's Federal Tax Legislative and Regulatory Services Group at: + 1 202 533 4366, 1801 K Street NW, Washington, DC 20006.